**SUPPLEMENTARY TABLE. Sensitivity analyses examining case definition uncertainties for mpox case-patients and sexually transmitted infection control patients — New York, 2022**

|  |  |  |
| --- | --- | --- |
| **Sensitivity analysis** | **mpox case-patients**  | **STI control patients** |
| **No. (%)** | **No. (%)** | **VE (95% CI)** |
| **A. Exclude persons aged ≥50 years** |
| ***Total*** | *221* | *219* | *--* |
| **Unvaccinated** | 201 (91.0) | 178 (81.3) | *ref.* |
| **Vaccinated** |
| 0–13 days after first dose | 10 (4.5) | 7 (3.2) | < –100 (<–100 to 45.1) |
| ≥14 days after first dose | 8 (3.6) | 18 (8.2) | 69.8 (21.6 to 88.4) |
| ≥0 days after second dose | 2 (0.9) | 16 (7.3) | 87.3 (38.0 to 97.4) |
| ≥14 days after first dose or ≥0 days after second dose | 10 (4.5) | 34 (15.5) | 76.7 (47.4 to 89.7) |
| **B. Include secondary syphilis in control group** |
| ***Total*** | *252* | *326* | *--* |
| **Unvaccinated** | 230 (91.3) | 271 (83.1) | *ref.* |
| **Vaccinated** |
| 0–13 days after first dose | 10 (4.0) | 10 (3.1) | –57.7 (<–100 to 45.2) |
| ≥14 days after first dose | 10 (4.0) | 24 (7.4) | 52.7 (–9.3 to 79.5) |
| ≥0 days after second dose | 2 (0.8) | 21 (6.4) | 84.2 (24.4 to 96.7) |
| ≥14 days after first dose or ≥ 0 days after second dose | 12 (4.8) | 45 (13.8) | 64.8 (26.7 to 83.1) |
| **C. Limit controls to those testing because of symptoms or partner referral** |
| ***Total*** | *252* | *107* | *--* |
| **Unvaccinated** | 230 (91.3) | 90 (84.1) | *ref.* |
| **Vaccinated** |
| 0–13 days after first dose | 10 (4.0) | 2 (1.9) | –66.7 (<–100 to 67.9) |
| ≥14 days after first dose | 10 (4.0) | 10 (9.4) | 63.5 (–4.9 to 87.3) |
| ≥0 days after second dose | 2 (0.8) | 5 (4.7) | 64.0 (<–100 to 94.4) |
| ≥14 days after first dose or ≥ 0 days after second dose | 12 (4.8) | 15 (14.0) | 63.6 (8.0 to 85.6) |
| **D. Limit to persons with known race and ethnicity**  |
| ***Total*** | *243* | *212* | *--* |
| **Unvaccinated** | 224 (92.2) | 170 (80.2) | *ref.* |
| **Vaccinated** |
| 0–13 days after first dose | 9 (3.7) | 4 (1.9) | –44.2 (<–100 to 62) |
| ≥14 days after first dose | 8 (3.3) | 20 (9.4) | 75.7 (38.1 to 90.5) |
| ≥0 days after second dose | 2 (0.8) | 18 (8.5) | 88.8 (44.5 to 97.7) |
| ≥14 days after first dose or ≥0 days after second dose | 10 (4.1) | 38 (17.9) | 80.5 (56.1 to 91.3) |

**Abbreviations**: mpox = monkeypox; ref = referent; STI = sexually transmitted infection